


## Accepted Manuscript

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

Brian C. Healy, Bonnie I. Glanz, Jonathan D. Zurawski, Maria Mazzola, Tanuja Chitnis, Howard L. Weiner



PII: S0022-510X(18)30382-4  
DOI: doi:[10.1016/j.jns.2018.09.020](https://doi.org/10.1016/j.jns.2018.09.020)  
Reference: JNS 16024  
To appear in: *Journal of the Neurological Sciences*  
Received date: 26 April 2018  
Revised date: 6 September 2018  
Accepted date: 14 September 2018

Please cite this article as: Brian C. Healy, Bonnie I. Glanz, Jonathan D. Zurawski, Maria Mazzola, Tanuja Chitnis, Howard L. Weiner, Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. *Jns* (2018), doi:[10.1016/j.jns.2018.09.020](https://doi.org/10.1016/j.jns.2018.09.020)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

Brian C Healy,<sup>abc</sup> Bonnie I Glanz,<sup>ab</sup> Jonathan D Zurawski,<sup>ab</sup> Maria Mazzola,<sup>ab</sup> Tanuja Chitnis,<sup>ab</sup> Howard L Weiner<sup>ab</sup>

<sup>a</sup> Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA

<sup>b</sup> Department of Neurology, Harvard Medical School, Boston, MA, USA

<sup>c</sup> Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA

*Corresponding author:*

Brian C Healy, PhD

Partners Multiple Sclerosis Center, 60 Fenwood Road, Office 90020

Boston, MA, 02115-6128, USA

Email: bchealy@partners.org

Phone: (+1) 617-732-5376

## HIGHLIGHTS

- Subjects treated with glatiramer acetate and interferon beta were compared.
- Long-term clinical outcomes were similar in the groups.
- Baseline features were not predictive of treatment effect.

## ABSTRACT

**Objective:** Our goal was to compare subjects treated with glatiramer acetate (GA) and interferon-beta (IFN- $\beta$ ) in terms of long-term clinical outcomes.

**Methods:** Subjects enrolled in the CLIMB who initiated either GA or IFN- $\beta$  within five years of disease onset and prior to 2008 were identified (n=150 for GA and n=144 for IFN- $\beta$ ). The two treatment groups were compared in terms of long-term clinical outcomes: time to EDSS 4, time to EDSS 6 and EDSS score seven years after treatment initiation. Baseline confounders included in our analysis were age, gender, disease duration, attacks in the previous year, EDSS prior to treatment initiation, and year of treatment

Download English Version:

<https://daneshyari.com/en/article/11029406>

Download Persian Version:

<https://daneshyari.com/article/11029406>

[Daneshyari.com](https://daneshyari.com)